Balow JE - Search Results

1

Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy.

Boumpas DT, Austin HA 3rd, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Boumpas DT, et al. Among authors: balow je. Ann Intern Med. 1993 Sep 1;119(5):366-9. doi: 10.7326/0003-4819-119-5-199309010-00003. Ann Intern Med. 1993. PMID: 8338289 Clinical Trial.

2

Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course.

Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin Iii HA, Kopp JB. Branton MH, et al. Among authors: balow je. Medicine (Baltimore). 2002 Mar;81(2):122-38. doi: 10.1097/00005792-200203000-00003. Medicine (Baltimore). 2002. PMID: 11889412 Free article. No abstract available.

3

Therapy of membranous nephropathy in systemic lupus erythematosus.

Balow JE, Austin HA 3rd. Balow JE, et al. Semin Nephrol. 2003 Jul;23(4):386-91. doi: 10.1016/s0270-9295(03)00056-1. Semin Nephrol. 2003. PMID: 12923727 Review.

4

Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti-IgE Monoclonal Antibody in Systemic Lupus Erythematosus.

Hasni S, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Joyal E, Fike A, Manna Z, Auh S, Shi Y, Chan D, Carlucci P, Biehl A, Dema B, Charles N, Balow JE, Waldman M, Siegel RM, Kaplan MJ, Rivera J. Hasni S, et al. Among authors: balow je. Arthritis Rheumatol. 2019 Jul;71(7):1135-1140. doi: 10.1002/art.40828. Epub 2019 May 8. Arthritis Rheumatol. 2019. PMID: 30597768 Free PMC article. Clinical Trial.

5

Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy.

Austin HA 3rd, Illei GG, Braun MJ, Balow JE. Austin HA 3rd, et al. Among authors: balow je. J Am Soc Nephrol. 2009 Apr;20(4):901-11. doi: 10.1681/ASN.2008060665. Epub 2009 Mar 18. J Am Soc Nephrol. 2009. PMID: 19297556 Free PMC article. Clinical Trial.

6

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE. Illei GG, et al. Among authors: balow je. Arthritis Rheum. 2010 Feb;62(2):542-52. doi: 10.1002/art.27221. Arthritis Rheum. 2010. PMID: 20112381 Free PMC article. Clinical Trial.

7

Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies.

Malek R, Chong AY, Lupsa BC, Lungu AO, Cochran EK, Soos MA, Semple RK, Balow JE, Gorden P. Malek R, et al. Among authors: balow je. J Clin Endocrinol Metab. 2010 Aug;95(8):3641-7. doi: 10.1210/jc.2010-0167. Epub 2010 May 19. J Clin Endocrinol Metab. 2010. PMID: 20484479 Free PMC article.

8

Clinical presentation and monitoring of lupus nephritis.

Balow JE. Balow JE. Lupus. 2005;14(1):25-30. doi: 10.1191/0961203305lu2055oa. Lupus. 2005. PMID: 15732284 Review.

9

Progress in the treatment of proliferative lupus nephritis.

Balow JE, Austin HA 3rd. Balow JE, et al. Curr Opin Nephrol Hypertens. 2000 Mar;9(2):107-15. doi: 10.1097/00041552-200003000-00003. Curr Opin Nephrol Hypertens. 2000. PMID: 10757214 Review.

10

New prospects for treatment of lupus nephritis.

Balow JE, Boumpas DT, Austin HA 3rd. Balow JE, et al. Semin Nephrol. 2000 Jan;20(1):32-9. Semin Nephrol. 2000. PMID: 10651216 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results